CBER’s New Director “Marks” A New Era For Biologics Regulation
This article was originally published in RPM Report
Peter Marks takes over the top spot in the center for biologics at FDA after a four year training period as deputy director. His background appears well suited to what promises to be a transformative era in medicine.
You may also be interested in...
The US agency seeks candidates for the executive position in charge of its research policy apparatus.
Agency seeks candidates for the executive position in charge of its research policy apparatus.
Robert Califf’s nomination to return as FDA commissioner will raise protests about a ‘revolving door’ pathway between industry and agency. But, in this case, it may be more apt to talk about how Califf’s time outside FDA led to evolving views on the role of big data in drug regulation.